Shares of Piramal Pharma leapt 14% after the company disclosed a Q2 net profit of ₹5.58 crore, erasing a ₹99.2 crore loss from the same quarter last year.
Revenue surged 28% YoY to ₹2,617 crore, while EBITDA climbed to ₹348.7 crore—more than double the ₹158.7 crore reported a year earlier—lifting the margin to 13.3% from 7.8%.
Segment‑wise, the contract development and manufacturing segment topped the list with a 36% revenue jump to ₹1,424 crore; complex hospital generics up 32% to ₹849 crore, and consumer healthcare up 13% to ₹359 crore.
The firm added 22 new customers and completed 110 audits in FY27's first half, underpinning its decision to raise the FY27 revenue growth outlook to 19‑20% and signal a lift in profitability. Net debt stood at ₹4,859 crore.
Management foresees continued operating leverage and disciplined execution, aiming to further improve margins before the next earnings release on May 28.